Search Results for: 19

ROCKVILLE, Md., Aug. 26, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that SYN-004, the Company’s lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile), will be […]

— Two of Company’s Anti-Infective Programs to be Presented at Highly Regarded Scientific Conference: Pertussis and C. difficile — ROCKVILLE, Md., Aug. 19, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its novel

— Expanded Data from Phase II MS Trial to be Released Next Month; Plans on Course to Advance C. difficile and C-IBS Programs into the Clinic During 2014 — — Conference Call Today, August 14, 2014, at 8:30 a.m. (EDT); U.S. Participants Call (877) 870-4263 or Join Webcast at http://www.videonewswire.com/event.asp?id=100224 — ROCKVILLE, Md., Aug. 14,

— Keynote Speaker: Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, Cedars-Sinai Medical Center; Chairman, Synthetic Biologics’ C-IBS Clinical Advisory Board — ROCKVILLE, Md., Aug. 13, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and

— SYN-005 Program Targeting Pertussis Toxin to be Highlighted in Oral Presentation — ROCKVILLE, Md., Aug. 12, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its SYN-005 for the treatment of Pertussis will

— Conference Call Scheduled for Thursday, August 14, 2014, at 8:30 am EDT — ROCKVILLE, Md., Aug. 7, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it intends to release its financial results for the

— Executed Agreement with Evonik for Formulation Development, Analytical Services andClinical Drug Manufacturing — — Toxicology Study Nearing Completion; Phase I Clinical Trials Expected to Begin in Q4 — ROCKVILLE, Md., Aug. 5, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause

— Oral Presentation to Include Greater Detail on Clinical Outcomes, Including Significant and Unique Improvements in Cognition — ROCKVILLE, Md., July 31, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that Rhonda Voskuhl,

ROCKVILLE, Md., July 29, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that in view of the unusual market activity in the Company’s stock, the NYSE MKT (the “Exchange”) has contacted the Company in accordance

Company’s License from The University of Texas at Austin Covers Development of SYN-005 in Collaboration with Intrexon Corporation ROCKVILLE, Md., July 21, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today announced that Jennifer Maynard, Ph.D.,